Riskpilot← Back to searchSign inGet full accessABLY MEDICAL AS
ASActiveOrg 915108598Kjøpmannsgata 9, 6005 ÅlesundResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20159 employeesablymed.com
Revenue 2024
NOK 18,3M
+34% vs 2023
EBITDA margin
-15.4%
+47% vs 2023
Equity ratio
88.0%
Financial strength
Net profit 2024
NOK -3,1M
+50% vs 2023
| Revenue | NOK 18,3M | +34% |
| EBITDA | NOK -2,8M | +47% |
| Net profit | NOK -3,1M | +50% |
| Total assets | NOK 99,9M | +58% |
| Equity | NOK 87,9M | +74% |
| Employees | 9 | — |
Legal name
ABLY MEDICAL AS
Org number
915108598
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
19. mars 2015
Share capital
NOK 302 351
Employees
9 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder alene.
Company purpose
Fou virksomhet knyttet til helse og kulturteknologi, med spesialisering innen menneske- og maskininteraksjon. Selskapet skal arbeide for å oppnå bærekraftig utvikling gjennom sine aktiviteter og prosjekter.
Address
Kjøpmannsgata 9, 6005 Ålesund
Phone
+4740455150
Email
oslo@ablymed.com
Website
ablymed.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 13 339 | 16 798 | 7 638 | 13 648 | 18 342 |
| Staff expenses | −6 174 | −14 808 | −8 852 | −7 475 | −4 430 |
| EBITDA | −6 511 | −21 398 | −10 588 | −5 343 | −2 825 |
| Depreciation & amort. | −249 | −197 | −109 | −93 | −285 |
| EBIT | −6 760 | −21 595 | −10 697 | −5 435 | −3 110 |
| Net financials | −478 | −344 | −851 | −779 | 30 |
| Profit before tax | −7 238 | −21 940 | −11 548 | −6 214 | −3 080 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −7 238 | −21 940 | −11 548 | −6 214 | −3 080 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 31 648 | 50 718 | 48 401 | 63 338 | 99 931 |
| Equity | 18 713 | 37 863 | 36 296 | 50 608 | 87 918 |
| Long-term debt | 0 | 5 701 | 5 701 | 5 701 | 3 001 |
| Short-term debt | 12 935 | 7 154 | 6 404 | 7 029 | 9 012 |
| Total debt | 12 935 | 12 855 | 12 105 | 12 730 | 12 013 |
EBITDA margin
-15.4%
This company
15.8%
Market median
-197% vs market
20202024
Equity ratio
88.0%
This company
38.2%
Market median
+130% vs market
20202024
Return on equity
-3.5%
This company
18.4%
Market median
-119% vs market
20202024
Net profit margin
-16.8%
This company
8.1%
Market median
-307% vs market
20202024
Asset turnover
0.18×
This company
1.12×
Market median
-84% vs market
20202024
Debt / equity
0.14×
This company
0.62×
Market median
+77% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
MI Chief Executive Officer | Chief Executive Officer | 2023 |
CK Observer | Observer | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2025 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2025 | |
| Chairman | 2022 | |
| Former (5) | ||
| Board of Directors | 2020 – 2021 | |
| Board of Directors | 2022 – 2025 | |
| Board of Directors | 2020 – 2021 | |
| Board of Directors | 2020 – 2021 | |
| Chairman | 2020 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 41.69% | 41.69% | 2024 | |
| Company | 14.03% | 14.03% | 2023 | |
| Company | 13.64% | 13.64% | 2024 | |
| Company | 9.29% | 9.29% | 2024 | |
| Company | 6.68% | 6.68% | 2024 | |
| Company | 5.96% | 5.96% | 2024 | |
| Company | 4.65% | 4.65% | 2024 | |
| Company | 4.12% | 4.12% | 2024 | |
| Company | 4.12% | 4.12% | 2024 | |
| Company | 2.75% | 2.75% | 2024 | |
| Company | 1.83% | 1.83% | 2024 | |
Malvestio Spa | Company | 1.49% | 1.49% | 2024 |
| Company | 1.02% | 1.02% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Future Invest As
ABLY MEDICAL AS Board members of ABLY MEDICAL AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mikkel Ingstrup | Chief Executive Officer | 0 companies |
| Cristina Kvam Santos | Observer | 0 companies |
| Arve Voldsund | Board of Directors | 0 companies |
| Roman Rosenkranz | Board of Directors | 0 companies |
| Svein Olav Torø | Board of Directors | 0 companies |
| Jørn Dreyer | Board of Directors | 0 companies |
| Massimo Malvestio | Board of Directors | 0 companies |
| Irem Sözügecer | Board of Directors | 0 companies |
| Tore Andreas Frøysa Tønseth | Board of Directors | 0 companies |
| Bjørnar Reitan | Board of Directors | 0 companies |
| Kjell Are Furnes | Chairman | 0 companies |
| Peder Stette | Chairman | 0 companies |